Efficacy and safety with >3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosis
Teresa Coelho(Universidade do Porto), Morie A. Gertz(Medical University of South Carolina), John L. Berk(Boston University), Hartmut Schmidt(Université Paris-Sud), Peter Aquino(Akebia Therapeutics (United States)), Annabel Wang, Violaine Planté‐Bordeneuve(Université Paris-Est Créteil), Carol Whelan(The Royal Free Hospital), Thomas H. Brannagan(Columbia University), Isabel Conceição(Université Paris-Sud), Arnt V. Kristen(Heidelberg University), Brian Drachman(Penn Presbyterian Medical Center), Laura Obici(University of Pavia), Kemi Olugemo(Akebia Therapeutics (United States)), Anna Mazzeo(University of Messina), Michael Polydefkis(Université Paris-Sud), Josep Maria Campistol Plana(Hospital Clínic de Barcelona), Josep Gámez(Université Paris-Sud), Giampaolo Merlini(University of Pavia), Merrill D. Benson(Indiana University School of Medicine), P. James B. Dyck(Mayo Clinic), Arvind Narayana(Teva Pharmaceuticals (United States)), Peter D. Gorevic(Université Paris-Sud)
Cited by 0
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k